Anavex Life Sciences Corp (AVXL)

[sokol]

The potential ANAVEX®2-73 to treat various Orphan diseases adds value to the company.

''Orphan drug companies have used with tremendous success as part of their drug life cycle management, the strategy to extend the life of their product by devising a succession of multiple discrete indications for the orphan drug. This strategy is critical to the continued financial success for orphan drug companies, especially when facing the challenges of generic competition and the demise of the traditional blockbuster drug strategy. The advantage of using multiple indications is that it allows a company to progressively expand the drug’s market.

This Blog Post presents several biotechnology companies that have used the multiple indication strategy for orphan drugs successfully:

• Alexion Pharmaceuticals’ Soliris

• Celgene’s Revlimid

• Novartis’ Gleevec.''

https://orphandruganaut.wordpress.com/2015/02/18/orphan-drugs-the-power-of-multiple-indications/